国际肿瘤学杂志

国际肿瘤学杂志 ›› 2015, Vol. 42 ›› Issue (8): 589-592.doi: 10.3760/cma.j.issn.1673422X.2015.08.008

• 论著 • 上一篇    下一篇

尼妥珠单抗联合同期放化疗治疗局部晚期宫颈癌的近期疗效观察

伍楚蓉,唐武兵,杨文,陈永发,潘兴喜,张永胜,杨画,梁海春,黄红东   

  1. 528200 佛山，南方医科大学附属南海医院肿瘤一科（伍楚蓉、唐武兵、杨文、陈永发、潘兴喜、张永胜、杨画、梁海春）；北京世纪坛医院泌尿内科（黄红东）
  • 出版日期:2015-08-08 发布日期:2015-06-29
  • 通讯作者: 杨文，Email：fsnhyangwen@hotmail.com E-mail:fsnhyangwen@hotmail.com

A shortterm curative observation of nimotuzumab combined with concurrent intensitymodulated radiotherapy and chemotherapy in the treatment of locally advanced cervical cancer

WU  Chu-Rong, TANG  Wu-Bing, YANG  Wen, CHEN  Yong-Fa, PAN  Xing-Xi, ZHANG  Yong-Sheng, YANG  Hua, LIANG  Hai-Chun, HUANG  Hong-Dong   

  1. First Department of Oncology, Affiliated Nanhai Hospital of Nanfang Medical University, Foshan 528200, China
  • Online:2015-08-08 Published:2015-06-29
  • Contact: Yang Wen E-mail:fsnhyangwen@hotmail.com

PDF

1346

被引次数

5

摘要： 目的探讨尼妥珠单抗联合放化疗治疗局部晚期宫颈癌的疗效及不良反应。方法收集经组织病理确诊的Ⅲ期宫颈癌初诊患者60例，采用随机数字表法将患者随机分为两组，对照组(n=30)采用调强放疗和腔内后装治疗及周期化疗，观察组(n=30)除调强放疗和腔内后装治疗及周期化疗外，每周放疗前进行尼妥珠单抗200 mg治疗，共6～7次。结果全部病例放疗结束3个月后评价疗效。观察组：CR 20例、PR 5例、SD 4例，PD 1例，总有效率（CR+PR）为83.4%。对照组：CR 18例、PR 3例、SD 6例，PD 3例，总有效率为70.0%，两组差异有统计学意义（χ2=8.356，P＜0.05）。观察组与对照组主要不良反应为轻度的放射性直肠炎（16.7%∶13.3%）、放射性膀胱炎（10.0%∶10.0%）、恶心呕吐（50.0%∶46.7%）和白细胞降低（40.0%∶43.3%），两组差异均无统计学意义（χ2 =3.357，P=0.719； χ2 =2.717，P=0.925； χ2 =5.882，P=0.623； χ2 =4.728，P=0.687），无皮疹及过敏反应发生。结论尼妥珠单抗可提高局部晚期宫颈癌对放疗的敏感性，提高有效率，且不增加明显不良反应。

关键词: 宫颈肿瘤, 放射疗法, 药物疗法, 抗体, 单克隆, 尼妥珠单抗

Abstract: ObjectiveTo explore the efficacy and adverse effects of nimotuzumab combined with chemotherapy and radiotherapy in the treatment of locally advanced cervical cancer. MethodsSixty patients with stage Ⅲ cervical cancer by the histopathologic diagnosis were collected, and they were randomly divided into two groups using the random number table method. The control group (n=30) using intensitymodulated radiotherapy， intracavitary afterloading therapy and periodic chemotherapy, the observation group (n=30) in addition to the intensitymodulated radiotherapy， intracavitary afterloading therapy and periodic chemotherapy, the nimotuzumab (200 mg) was given to the patients before weekly radiotherapy. All patients were received 6 to 7 times of treatment. ResultsThe curative effects of all the patients were evaluated after radiotherapy 3 months. In the observation group, there were 20 cases of CR, 5 cases of PR, 4 cases of SD, 1 case of PD, the total effective rate (CR+PR) was 83.3%. In the control group, there were 18 cases of CR, 3 cases of PR, 6 cases of SD, 3 cases of PD, the total effective rate was 70.0%. The difference was statistically significant (χ2 =8.356, P＜0.05). The main adverse reactions in the observation group and control group included slight radioactive proctitis (16.7% vs 13.3%), radioactive cystitis (10.0% vs 10.0%), nausea and vomiting (50.0% vs 46.7%),  reduction of white blood cells (40.0% vs 43.3%), with no significant differences (χ2 =3.357, P=0.719; χ2 =2.717, P=0.925; χ2 =5.882, P=0.623; χ2 =4.728, P=0.687). There were no skin rashes and allergic reactions. ConclusionNimotuzumab can enhance the locally stage cervical cancer patients′ sensitivity on radiotherapy, which can increase the efficacy and doesn′t increase adverse reaction obviously.

Key words: Uterine cervical neoplasms, Radiotherapy, Drug therapy, Antibodies, monoclonal, Nimotuzumab